Sage Journals: Discover world-class research

Retricted access

Research article

First published 2020-6

Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity

Shinya Hirahara, Yasuhiro Katsumata, Hidenaga Kawasumi [...]

Lupus

Retricted access

Research article

First published 2017-06

Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone

Megan L. Cramer, Guohong Shao, Louise R. Rodino-Klapac [...]

Human Gene Therapy

Free access

Review article

First published 2017-5

Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

Nathan D. Gay, Craig Y. Okada, Andy I. Chen [...]

Therapeutic Advances in Hematology

Open access

Research article

First published 2024

Clinical Experience of External Application of Clearing Heat and Removing Dampness in Relieving Grade 2 to 3 Rash Caused by Programed Cell Death Protein 1 (PD-1)/Programed Cell Death Ligand 1 (PD-L1) Inhibitors: A Single-Center Retrospective Study

Shu-yi Chen, Fang-min Zhao, Rui Yu [...]

Integrative Cancer Therapies

Open access

Research article

First published 2020

Optimizing Sequence of PD-L1 Immune-Checkpoint Inhibitors and Radiation Therapy in Bladder Cancer

Côme Tholomier, Gautier Marcq, Surashri Shinde-Jadhav [...]

Bladder Cancer

Open access

Research article

First published 2024

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy

Aditya Bardia, Lajos Pusztai, Kathy Albain [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2025

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy [...]

Therapeutic Advances in Medical Oncology

Open access

Research article

First published 2023

Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer

Yu Zhao, Zhe Wang, Xiuhuan Shi [...]

Technology in Cancer Research & Treatment

Free access

Review article

First published 2017-3

Nivolumab in renal cell carcinoma: latest evidence and clinical potential

Camille Mazza, Bernard Escudier, Laurence Albiges

Therapeutic Advances in Medical Oncology

Retricted access

Case report

First published 2023-3

Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma

Laurence Bonhomme-Faivre, Valentina Guarino, Srimanta C Misra

Journal of Oncology Pharmacy Practice

Search results